Acute temozolomide induced liver injury: Mixed type hepatocellular and cholestatic toxicity

Basit Öğe Kaydı
dc.authorid0000-0003-0128-6947
dc.authorid0000-0002-0901-9192
dc.contributor.authorAygün, Cem
dc.contributor.authorYıldırım Altınok, Ayşe
dc.contributor.authorÇakır, Aslı
dc.contributor.authorAğan, Ahmet Faruk
dc.contributor.authorBalaban, Yasemin
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:36:40Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:36:40Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı
dc.description.abstractTemozolomide (TMZ) is an oral imidazotetrazine methylating agent which is used for the treatment of glioblastoma multiforme (GBM). We report a case of acute hepatotoxicity in a 53-year old male patient after administration of TMZ for GBM. He had fatigue, nausea, anorexia and jaundice. His laboratory analysis showed alanine aminotransferase(ALT): 632 IU/L (normal range 0-40); aspartate aminotransferase(AST): 554 IU/L (normal range 5-34); alkaline phosphatase(ALP): 1143 IU/L (normal range 40-150); ?-glutamyl transpeptidase(GGT): 514 IU/L (normal range 9-64 IU/L); total bilirubin: 15.1 mg/dL (normal range 0-1.2); direct bilirubin: 13.2 mg/dL and prothrombin time(PT): 13.5 s, with international normalized ratio (INR): 1.1 (normal range 0.8-1.2). His liver biopsy specimen showed mixed-type (both hepatocellular and cholestatic) hepatic injury, compatible with a diagnosis of drug-induced hepatitis. An objective causality assessment using the Naranjo probability scale suggested that TMZ was the probable cause of the acute hepatitis. His liver function tests gradually normalized in 6 months after discontinuation of the drug. In susceptible individuals, TMZ use may lead to acute mixed type liver toxicity. Complete recovery may be possible if the drug is discontinued before severe liver injury is established.
dc.identifier.citationAygün, C., Yıldırım Altınok, A., Çakır, A., Ağan, A. F. ve Balaban, Y. (2016). Acute temozolomide induced liver injury: Mixed type hepatocellular and cholestatic toxicity. Acta Gastro-Enterologica Belgica, 79(4), 487-489.
dc.identifier.endpage489
dc.identifier.issn1784-3227
dc.identifier.issue4
dc.identifier.scopusqualityQ3
dc.identifier.startpage487
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1228
dc.identifier.volume79
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherUniversa Press
dc.relation.ispartofActa Gastro-Enterologica Belgicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectDrug-Induced Cholestatic Hepatitis
dc.subjectTemozolomide
dc.subjectDrug-Induced
dc.subjectCholestatic Hepatitis
dc.titleAcute temozolomide induced liver injury: Mixed type hepatocellular and cholestatic toxicity
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Aygun, Cem-2016.pdf
Boyut:
1.12 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu